Yale’s Endocrine Neoplasia Program Is Flourishing
The Yale Multidisciplinary Endocrine Neoplasia Clinic has been treating benign and malignant diseases of the thyroid, parathyroid, adrenal, and pituitary glands since 2013. The program is a collaboration between the Department of Internal Medicine’s Section of Endocrinology & Metabolism and Yale Cancer Center and Smilow Cancer Hospital.
Doctors seeing success in HPV vaccine against cancers
(WTNH) – The only vaccine to prevent cancer has been on the market for a number of years, but doctors are now seeing the actual generation benefiting. It’s the HPV vaccine, which can prevent cervical cancer and it’s proving to be extremely effective. Doctor Elena Ratner, a gynecologic oncologist at Yale Cancer Center and Smilow Hospital says success is being seen as a result of Gardasil 9, the vaccine to prevent HPV, which is a sexually-transmitted disease that can lead to cancers.Source: WTNH
Yale expert familiar with procedure used on First Lady Jill Biden’s skin cancer
In light of First Lady Jill Biden's diagnosis and subsequent treatment for basal cell cancer, Yale dermatologic surgeons David Leffell, MD explains the symptoms of the condition and expands on the Moh's surgery technique used to remove the First Lady's cancer.Source: WTNH News8
Experts Study Implications of Genetic Markers in Prostate Cancer
In this video, Stacy Loeb, MD, MSc, and Veda N. Giri, MD, discuss the European Urology paper “Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention,” for which they served as coauthors. Giri is division chief of Clinical Cancer Genetics for Yale Cancer Center and Smilow Cancer and assistant director of Clinical Cancer Genetics for Yale Cancer Center, New Haven, Connecticut. Loeb is a professor in the departments of urology and population health at the NYU Grossman School of Medicine, New York City, New York.Source: Urology Times
HER2 Low Breast Cancer: New Clinical Entity or Testing Artifact
Should breast cancer patients with low but not negative tumor expression of HER2 be considered a distinct patient group that can be treated differently from patients with tumors that are HER2 negative or HER2 positive? That was the question posed during a session at the recent San Antonio Breast Cancer Symposium (SABCS) 2022.Source: Medscape
The VA Launches Largest-Ever Trial on Screening Methods for Liver Cancer
The largest clinical trial in history related to liver cancer screening is launching in 2023, funded by the Department of Veterans Affairs. The project is scheduled to recruit 4,700 veterans with cirrhosis from 47 VA medical centers. Cirrhosis is a major risk factor for liver cancer and affects veterans disproportionally.
New Treatments Keeping Women Alive Longer Through Breast Cancer
Five percent of women diagnosed with breast cancer have metastatic disease, but survival rates are climbing. According to the Breast Cancer Research Foundation, the number of women living with metastatic breast cancer rose to 168,000 last year from 155,000 the year before. New breakthroughs keep women alive longer while researchers race to find the next therapy that will work.Source: WINK
Yale Cancer Center Study Characterizes Link Between Drug Resistance and Central Nervous System Relapse
A new study from Yale Cancer Center characterizes the functional link between drug resistance and central nervous system (CNS) relapse. The findings from a study led by Don Nguyen, PhD, BS, Associate Professor of Pathology and Medicine (Medical Oncology) and Assistant Yale Cancer Center Director for Research Development, were recently published in the journal Nature Communications.
Five Questions With: Dr. Joseph Renzulli, Dr. Sanjay Aneja and Dr. Matthew Austin
WESTERLY HOSPITAL RECENTLY launched its first multidisciplinary genitourinary oncology clinic, which brings together the expertise of urologic oncology, medical oncology and radiation oncology to treat patients with genitourinary cancers. Pictured from left: Robert Legare, regional medical director of the Smilow Cancer Hospital Care Center at Westerly Hospital; Dr. Matthew Austin, medical oncologist at Westerly Hospital; Rachel Drake, registered nurse; Dr. Sanjay Aneja, radiation oncologist at Westerly Hospital; and Dr. Joseph Renzulli, regional medical director and chief of urology at Westerly Hospital. / COURTESY WESTERLY HOSPITALSource: PBN
Emerging Treatment Options in the Management of Resistance to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
Targeted therapies and immune checkpoint inhibitors have transformed the treatment landscape for non–small cell lung cancer (NSCLC). Tyrosine kinase inhibitors (TKIs) have contributed to an overall decline in lung cancer–related mortality, and as they move into the early-stage setting, more dramatic improvements in outcomes are expected. However, combatting TKI resistance in NSCLC is largely an unmet challenge. Tissue next-generation sequencing and plasma circulating tumor DNA–based assays have emerged as concurrent methods to identify targetable mechanisms of resistance to TKIs at the time of clinical progression, while antibody-drug conjugates represent a promising therapeutic class for the treatment of TKI-resistant NSCLC.Source: ASCO Daily News
2022 BioCT Entrepreneur of the Year
Dr. Ranjit Bindra of Yale University has been named the 2022 BioCT Entrepreneur of the Year. Dr. Bindra is an internationally recognized academic physician-scientist at the Yale School of Medicine who has also founded and/or co-founded several companies based on work from his laboratory and collaborators at Yale.Source: BioCT
Sickle Cell Cure will be Cost-Effective if Health Disparities Considered -Study Finds
Dec 13 (Reuters) - Multimillion-dollar gene therapies being tested for sickle cell disease will be cost-effective in the United States if health disparities tied in part to decreased access to healthcare are taken into account, researchers said at a meeting of blood-disease specialists.Source: Reuters
‘This is About Saving Women’s Lives’: Find It Early Act Aims to Increase Breast Cancer Screenings
Congresswoman Rosa DeLauro announced the introduction of the Find It Early Act which, if passed, would require insurance companies to cover mammograms, breast ultrasounds, and MRIs to increase early cancer detection.
Ignoring Back Pain Can Be a Big Pancreatic Cancer Mistake, Doctors Say
The symptoms of pancreatic cancer may be subtle, varied, or—in the early stages of the disease—non-existent. That's why "pancreatic cancer is the most lethal cancer in the human body, with overall five-year survival rates at just about seven percent despite all the advances over the past decades," according to the Mayo Clinic News Network. "There are no telltale signs for pancreatic cancer, and symptoms like weight loss, abdominal pain, jaundice, and appetite loss are nonspecific."Source: Yahoo Life
Panel to Examine the Ongoing Evolution of Antibody Drug Conjugates in the Treatment of Breast Cancer
Antibody drug conjugates (ADCs), which use a targeted monoclonal antibody to deliver a cytotoxic payload, are among the most effective breast cancer therapies yet developed. The first Food and Drug Administration approval of an ADC in breast cancer, ado-trastuzumab emtansine, better known as T-DM1, sparked development of numerous new and promising ADCs for breast cancer.Source: SABCS Meeting News